Article

New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer

Author(s):

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Click here to view this article.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Christine Frissora, MD | Credit: Weill Cornell
Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024
4 experts are featured in this series.
4 experts are featured in this series.
© 2024 MJH Life Sciences

All rights reserved.